197 related articles for article (PubMed ID: 22477184)
21. The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation.
Alawi K; Keeble J
Pharmacol Ther; 2010 Feb; 125(2):181-95. PubMed ID: 19896501
[TBL] [Abstract][Full Text] [Related]
22. Involvement of capsaicin-sensitive afferents and the Transient Receptor Potential Vanilloid 1 Receptor in xylene-induced nocifensive behaviour and inflammation in the mouse.
Sándor K; Helyes Z; Elekes K; Szolcsányi J
Neurosci Lett; 2009 Feb; 451(3):204-7. PubMed ID: 19159661
[TBL] [Abstract][Full Text] [Related]
23. Case report of atopic dermatitis with refractory pruritus markedly improved with the novel use of clonidine and trimeprazine.
Genois A; Haig M; Des Roches A; Sirard A; Le May S; McCuaig CC
Pediatr Dermatol; 2014; 31(1):76-9. PubMed ID: 22747704
[TBL] [Abstract][Full Text] [Related]
24. Dopamides, vanillylamides, ethanolamides, and arachidonic acid amides of anti-inflammatory and analgesic drug substances as TRPV1 ligands.
Sinning C; Watzer B; De Petrocellis L; Di Marzo V; Imming P
ChemMedChem; 2008 Dec; 3(12):1956-64. PubMed ID: 19003845
[TBL] [Abstract][Full Text] [Related]
25. Transient receptor potential vanilloid 1 agonists as candidates for anti-inflammatory and immunomodulatory agents.
Tsuji F; Murai M; Oki K; Seki I; Ueda K; Inoue H; Nagelkerken L; Sasano M; Aono H
Eur J Pharmacol; 2010 Feb; 627(1-3):332-9. PubMed ID: 19878665
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of 5-substituted and 4,5-disubstituted-2-arylamino oxazole TRPV1 antagonists.
Perner RJ; Koenig JR; Didomenico S; Gomtsyan A; Schmidt RG; Lee CH; Hsu MC; McDonald HA; Gauvin DM; Joshi S; Turner TM; Reilly RM; Kym PR; Kort ME
Bioorg Med Chem; 2010 Jul; 18(13):4821-9. PubMed ID: 20570528
[TBL] [Abstract][Full Text] [Related]
27. The transient receptor potential vanilloid 1: role in airway inflammation and disease.
Geppetti P; Materazzi S; Nicoletti P
Eur J Pharmacol; 2006 Mar; 533(1-3):207-14. PubMed ID: 16464449
[TBL] [Abstract][Full Text] [Related]
28. A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers.
Gibson RA; Robertson J; Mistry H; McCallum S; Fernando D; Wyres M; Yosipovitch G
PLoS One; 2014; 9(7):e100610. PubMed ID: 25047038
[TBL] [Abstract][Full Text] [Related]
29. The role of TRPV1 channel in aged human skin.
Lee YM; Kang SM; Chung JH
J Dermatol Sci; 2012 Feb; 65(2):81-5. PubMed ID: 22154816
[TBL] [Abstract][Full Text] [Related]
30. Mu-opioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain.
Endres-Becker J; Heppenstall PA; Mousa SA; Labuz D; Oksche A; Schäfer M; Stein C; Zöllner C
Mol Pharmacol; 2007 Jan; 71(1):12-8. PubMed ID: 17005903
[TBL] [Abstract][Full Text] [Related]
31. Novel therapeutic approach with PAC-14028 cream, a TRPV1 antagonist, for patients with mild-to-moderate atopic dermatitis.
Song PI; Armstrong CA
Br J Dermatol; 2019 May; 180(5):971-972. PubMed ID: 31025744
[No Abstract] [Full Text] [Related]
32. Pharmacology of vanilloid transient receptor potential cation channels.
Vriens J; Appendino G; Nilius B
Mol Pharmacol; 2009 Jun; 75(6):1262-79. PubMed ID: 19297520
[TBL] [Abstract][Full Text] [Related]
33. Anti-pruritic and anti-inflammatory effects of natural verbascoside through selective inhibition of temperature-sensitive Ca
Sun X; Qi H; Wu H; Qu Y; Wang K
J Dermatol Sci; 2020 Mar; 97(3):229-231. PubMed ID: 31983608
[No Abstract] [Full Text] [Related]
34. Emerging therapies for atopic dermatitis: TRPV1 antagonists.
Bonchak JG; Swerlick RA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S63-S66. PubMed ID: 29248524
[TBL] [Abstract][Full Text] [Related]
35. Transient receptor potential vanilloid 1 mediates hyperalgesia and is up-regulated in rats with chronic pancreatitis.
Xu GY; Winston JH; Shenoy M; Yin H; Pendyala S; Pasricha PJ
Gastroenterology; 2007 Oct; 133(4):1282-92. PubMed ID: 17698068
[TBL] [Abstract][Full Text] [Related]
36. Triazine-based vanilloid 1 receptor open channel blockers: design, synthesis, evaluation, and SAR analysis.
Vidal-Mosquera M; Fernández-Carvajal A; Moure A; Valente P; Planells-Cases R; González-Ros JM; Bujons J; Ferrer-Montiel A; Messeguer A
J Med Chem; 2011 Nov; 54(21):7441-52. PubMed ID: 21950613
[TBL] [Abstract][Full Text] [Related]
37. Transient receptor potential vanilloid 1, calcitonin gene-related peptide, and substance P mediate nociception in acute pancreatitis.
Wick EC; Hoge SG; Grahn SW; Kim E; Divino LA; Grady EF; Bunnett NW; Kirkwood KS
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G959-69. PubMed ID: 16399878
[TBL] [Abstract][Full Text] [Related]
38. PAR2 Mediates Itch via TRPV3 Signaling in Keratinocytes.
Zhao J; Munanairi A; Liu XY; Zhang J; Hu L; Hu M; Bu D; Liu L; Xie Z; Kim BS; Yang Y; Chen ZF
J Invest Dermatol; 2020 Aug; 140(8):1524-1532. PubMed ID: 32004565
[TBL] [Abstract][Full Text] [Related]
39. Capsaicin receptor: TRPV1 a promiscuous TRP channel.
Pingle SC; Matta JA; Ahern GP
Handb Exp Pharmacol; 2007; (179):155-71. PubMed ID: 17217056
[TBL] [Abstract][Full Text] [Related]
40. Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons.
Niiyama Y; Kawamata T; Yamamoto J; Omote K; Namiki A
Neuroscience; 2007 Aug; 148(2):560-72. PubMed ID: 17656027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
